October 26, 2012
Shares of biotech Agenus (Nasdaq: AGEN ) appreciated almost 5% today, after the company posted its 3rd quarter earnings. The company's key compound, QS-21 Stimulon, is licensed to some of the biggest players in the pharmaceutical space, ,including GlaxoSmithKline (NYSE: GSK ) and Janssen, which is a subsidiary of Johnson & Johnson (NYSE: JNJ ) .
In the following video, health care analysts Max Macaluso and David Williamson discuss the company's latest quarter and a few things Agenus investors should watch.
Biotech companies can be some of the most exciting-and riskiest-investments on the market. However, it's essential to balance speculative plays in your portfolio with stocks that can help you build long-term weatlh. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you retire well, and also include some winning wealth-building strategies that every investor should know. Click here now to keep reading.